MX2018004547A - Nuevos anticuerpos fv multivalentes. - Google Patents

Nuevos anticuerpos fv multivalentes.

Info

Publication number
MX2018004547A
MX2018004547A MX2018004547A MX2018004547A MX2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A
Authority
MX
Mexico
Prior art keywords
diabody
multivalent
antibodies
chain
scfv
Prior art date
Application number
MX2018004547A
Other languages
English (en)
Inventor
Weichel Michael
Mueller Thomas
Reusch Uwe
ELLWANGER Kristina
FUCEK Ivica
RAJKOVIC Erich
Treder Martin
Ross Thorsten
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of MX2018004547A publication Critical patent/MX2018004547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Abstract

Se describe una molécula de anticuerpo triespecífica que comprende una unidad de diacuerpo integrada en una cadena polipeptídica que tiene al menos seis dominios variables unidos uno tras otro. En ciertos casos se conectan distalmente dos fragmentos de Fv de cadena sencilla (scFv) a la unidad de diacuerpo proporcionando dos sitios de unión al antígeno adicionales (Fig. 1 y 2).
MX2018004547A 2015-10-13 2016-10-13 Nuevos anticuerpos fv multivalentes. MX2018004547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (1)

Publication Number Publication Date
MX2018004547A true MX2018004547A (es) 2018-11-09

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004547A MX2018004547A (es) 2015-10-13 2016-10-13 Nuevos anticuerpos fv multivalentes.

Country Status (13)

Country Link
US (1) US11572415B2 (es)
EP (2) EP3156417A1 (es)
JP (1) JP6936497B2 (es)
KR (1) KR20180057720A (es)
CN (1) CN108473577A (es)
AU (1) AU2016336866B2 (es)
BR (1) BR112018007445A2 (es)
CA (1) CA3001765A1 (es)
IL (1) IL258638B2 (es)
MX (1) MX2018004547A (es)
SG (2) SG11201803083XA (es)
WO (1) WO2017064221A1 (es)
ZA (1) ZA201802543B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890041A1 (ru) 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
JP7474193B2 (ja) * 2017-06-25 2024-04-24 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
MX2020009445A (es) 2018-03-14 2020-10-08 Affimed Gmbh Proteina de union al antigeno egfr/cd16 biespecifica.
CN117285641A (zh) * 2018-03-27 2023-12-26 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
WO2019199916A1 (en) * 2018-04-13 2019-10-17 Eli Lilly And Company Fab-based trispecific antibodies
JP2021521275A (ja) 2018-04-13 2021-08-26 アフィメド ゲーエムベーハー Ｎｋ細胞結合抗体融合構築物
US20210179734A1 (en) * 2018-04-17 2021-06-17 Invenra Inc. Trivalent trispecific antibody constructs
MX2021002332A (es) 2018-08-27 2021-08-11 Affimed Gmbh Células nk crioreservadas precargadas con una construcción de anticuerpo.
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
EP4054649A4 (en) * 2019-11-06 2023-12-06 Systimmune, Inc. GUIDANCE AND NAVIGATION REGULATORY PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
EP4255931A1 (en) * 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
CN116897166A (zh) * 2021-02-19 2023-10-17 信达生物制药(苏州)有限公司 抗GPRC5DxBCMAxCD3三特异性抗体及其用途
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
WO2023056313A1 (en) * 2021-09-29 2023-04-06 Modex Therapeutics Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
JPH09508009A (ja) * 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
EP1294904A1 (en) * 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
RU2004122702A (ru) 2001-12-26 2005-04-20 Иммуномедикс, Инк. (Us) Способы получения полиспецифичных, поливалентных средств из vh и vl доменов
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2925782B1 (en) * 2012-12-03 2020-01-22 NovImmune SA Anti-cd47 antibodies and methods of use thereof
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
WO2014201378A1 (en) * 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EA201890041A1 (ru) * 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител

Also Published As

Publication number Publication date
RU2018126966A3 (es) 2020-04-20
BR112018007445A2 (pt) 2019-12-10
IL258638B2 (en) 2023-04-01
AU2016336866B2 (en) 2023-05-25
EP3156417A1 (en) 2017-04-19
IL258638B (en) 2022-12-01
CN108473577A (zh) 2018-08-31
KR20180057720A (ko) 2018-05-30
US11572415B2 (en) 2023-02-07
JP2018537415A (ja) 2018-12-20
AU2016336866A1 (en) 2018-05-10
RU2018126966A (ru) 2020-02-10
EP3362478A1 (en) 2018-08-22
SG10202004094VA (en) 2020-05-28
US20190040155A1 (en) 2019-02-07
SG11201803083XA (en) 2018-05-30
CA3001765A1 (en) 2017-04-20
WO2017064221A1 (en) 2017-04-20
ZA201802543B (en) 2020-01-29
IL258638A (en) 2018-06-28
JP6936497B2 (ja) 2021-09-15

Similar Documents

Publication Publication Date Title
MX2018004547A (es) Nuevos anticuerpos fv multivalentes.
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
DK3638698T3 (da) Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
PH12017500890A1 (en) Antibody drug conjugates
BR112018015480A2 (pt) proteínas de ligação ao antígeno que se ligam a pd-l1
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
AR105267A1 (es) Anticuerpos de unión a tau
MX2015012540A (es) Ratón de cadena ligera común.
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
MX2016011809A (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
WO2016205427A3 (en) Binding proteins against vegf, pdgf, and/or their receptors
AU2024202102A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
WO2016100533A3 (en) Intercalated single-chain variable fragments
EP3144676A4 (en) Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
AR106198A1 (es) Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3)
TH118570B (th) แอนทิบอดีที่จำเพาะหลายตำแหน่ง (multispecific antibodies) ที่ประกอบด้วยแอนทิบอดีที่มีความยาวสมบูรณ์และชิ้นส่วน Fab สายเดี่ยว